Literature DB >> 28176163

Retrospective analysis of 55 twin neonates with haemolytic disease of the newborn.

Hu Zhao1, Bijuan Li2, Ning Li1, Yamei Shen1, Kailiang Liu1, Xiangwu Shu1, Cheng Mei1, Lanlan Tang1.   

Abstract

Haemolytic disease is a condition characterized by anaemia and jaundice, and the course may be more complicated in twins. We investigated the demographic and laboratory characteristics of twins with haemolytic disease of the newborn (HDN) and compared these characteristics between groups categorized according to multiple birth status (twins vs. singletons) and conception method (assisted reproductive technology (ART) vs. spontaneous conception). Fifty-five twins with HDN and 253 singletons with HDN who were born during the same period (controls) were included in the study, and we performed comparisons between them. The results showed that twin infants were more likely to be premature, have a low birth weight and be conceived via ART than their singleton counterparts. Moreover, a variety of comorbidities were identified more frequently in twins with HDN than singletons with HDN. The minimum haemoglobin and the initial and maximum total bilirubin, albumin and complement 3 (C3) were all significantly lower in twins than in singletons; however, these two groups were not found to differ significantly by direct antiglobulin test (DAT) status. Twins conceived via ART had a lower minimum haemoglobin and initial bilirubin than twins conceived spontaneously. The results of this study suggested that neonatal comorbidities were more common in twins with HDN than singletons with HDN; however, DAT positivity did not appear to play a major role in the higher rates of comorbidities and lower concentration of haemoglobin observed in twins. Among twins with HDN, conception via ART may serve as a risk factor for increased disease severity.

Entities:  

Keywords:  Assisted reproductive technology; Direct antiglobulin test; Haemolytic disease of the newborn; Twins

Mesh:

Substances:

Year:  2017        PMID: 28176163     DOI: 10.1007/s12026-017-8902-6

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  36 in total

1.  A case of rhesus incompatibility occurring in a twin pregnancy.

Authors:  R S HYSLOP; W WHILEY
Journal:  Med J Aust       Date:  1960-04-16       Impact factor: 7.738

2.  [Erythroblastosis in twins].

Authors:  H W KAYSER
Journal:  Zentralbl Gynakol       Date:  1955

3.  Twin pregnancy complicated by severe hemolytic disease of the fetus and newborn due to anti-g and anti-C.

Authors:  Thomas N Trevett; Kenneth J Moise
Journal:  Obstet Gynecol       Date:  2005-11       Impact factor: 7.661

4.  Middle cerebral artery-peak systolic velocity in dizygotic twins with anti-E alloimmunization.

Authors:  Yumiko Satake; Yukiyasu Sato; Noriomi Matsumura; Keiji Tatsumi; Hiroshi Fujiwara; Ikuo Konishi
Journal:  J Obstet Gynaecol Res       Date:  2010-10-11       Impact factor: 1.730

5.  [ABO-erythroblastosis demonstrated in twins].

Authors:  P Speiser; A Rosenkranz; F Langer
Journal:  Wien Med Wochenschr       Date:  1968-06-01

6.  Three decades of twin births in the United States, 1980-2009.

Authors:  Joyce A Martin; Brady E Hamilton; Michelle J K Osterman
Journal:  NCHS Data Brief       Date:  2012-01

Review 7.  Monozygotic twinning, cerebral palsy and congenital anomalies.

Authors:  P O D Pharoah; Y Dundar
Journal:  Hum Reprod Update       Date:  2009-05-19       Impact factor: 15.610

8.  Variable Clinical Presentations of ABO Incompatibility in Dizygotic Twins.

Authors:  Cynthia A Mundy; Jatinder Bhatia
Journal:  Neonatal Netw       Date:  2015

9.  A decline in the frequency of neonatal exchange transfusions and its effect on exchange-related morbidity and mortality.

Authors:  Laurie A Steiner; Matthew J Bizzarro; Richard A Ehrenkranz; Patrick G Gallagher
Journal:  Pediatrics       Date:  2007-07       Impact factor: 7.124

Review 10.  Anti-D prophylaxis: past, present and future.

Authors:  M de Haas; K Finning; E Massey; D J Roberts
Journal:  Transfus Med       Date:  2014-02       Impact factor: 2.019

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.